Home  /  Resource Library  /  Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post Treatment MRD Recurrence

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post Treatment MRD Recurrence

ASH 2021